Skip to content

Trial Summary

A Phase 2, Randomized Study of Neoadjuvant Nivolumab plus Ipilimumab followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab plus Ipilimumab followed by Either Adjuvant Nivolumab or Postsurgical Observation Depending on Pathologic Response Compared with Adjuvant Nivolumab in Treatment-Naive Patients with Resectable Clinically Detectable Stage III Melanoma

Acronym:

CA209-7UA

ACTRN/NCT /ethics:

NCT04495010

Scientific title:

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA)

Sponsor / Cooperative group:

Bristol-Myers Squibb

Trial & Patient Characteristics

Cancer TypeMelanoma & other skin
Trial TypeTreatment
PhasePhase II
Age Range12 years and older
SexBoth
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2020-09-28
Anticipated End Date2027-10-23

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorProfessor Michael Brown
Recruitment StatusRecruitment on hold